GHRP-2 Peptide 5mg

 

Growth hormone releasing peptide-2 (GHRP-2) is a synthetic analog of ghrelin, a gastrointestinal peptide that binds to the growth hormone secretagogue receptor (GHS-R). Ghrelin increases growth hormone release as well as hunger.¹ In a similar way, GHRP-2 activates GHS-R triggering the release of GH. Both ghrelin and GHRP-2 also stimulate the release of prolactin, cortisol, and corticotropin from the anterior pituitary gland.² GHRP-2 contains 6 amino acids and has a molecular weight of 818 kDa. Despite the different chemistry of natural ghrelin and GHRP-2, evidence strongly supports that they have the same biological actions as discussed above.³ GHRP-2 acts in two ways to boost natural growth hormone levels. First, GHRP-2 amplifies the endogenous signal for growth hormone secretion by interaction with GHS-R, resulting in substantial growth hormone release.³ In a lab experiment, GHRP-2 significantly increased the release of growth hormone in mice carrying a genetic mutation in natural growth hormone releasing hormone (GHRH).⁴ Second, it suppresses somatostatin, which inhibits growth hormone.⁵ Furthermore, GHRP-2 has been shown to work in conjunction with the growth hormone-releasing factor (GRF) to release growth hormone from the pituitary gland of rats.⁵ Animal and human studies show GHRP-2 increases food intake.^3,6 In addition to this, GHRP-2 improves muscle growth⁷, immunity⁸, sleep quality⁹, and may protect the heart.¹⁰ Further, GHRP-2 increases the release of insulin-like growth factor I (IGF-I).¹¹ A study found that intraperitoneal injection of GHRP-2 reduced tissue necrotic factor-alpha (TNF-α) in a rat model of liver damage, suggesting a role of GHRP-2 in inflammation.¹² GHRP-2 is a useful reagent used in in vitro experiments with its multidimensional effects. GHRP-2 comes in a vial as a lyophilized powder (5 mg/vial). The vial content can be reconstituted with a convenient volume of sterile water and used in vitro studies.

References: Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4679-84. 2. Veldhuis JD, Roemmich JN, Richmond EJ, Bowers CY. Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocr Rev. 2006 Apr;27(2):101-40. 3. Titterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. Endocrinology. 2009 Dec;150(12):5478-87. 4. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005 Feb;90(2):611-4. 5. Cheng J, Wu TJ, Butler B, Cheng K. Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci. 1997;60(16):1385-92. 6. Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab. 2003 Sep;16(7):981-5. 7. Hu R, Wang Z, Peng Q, Zou H, Wang H, Yu X, Jing X, Wang Y, Cao B, Bao S, Zhang W, Zhao S, Ji H, Kong X, Niu Q. Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation. PLoS One. 2016 Feb 19;11(2):e0149461. 8. Taub DD, Murphy WJ, Longo DL. Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways. Curr Opin Pharmacol. 2010 Aug;10(4):408-24. 9. Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997 Oct;66(4):278-86. 10. Muccioli G, Broglio F, Valetto MR, Ghè C, Catapano F, Graziani A, Papotti M, Bisi G, Deghenghi R, Ghigo E.Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris). 2000 Feb;61(1):27-31.9. 11. Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004 May;89(5):2290-300.

Click here to read more about GHRP-2 peptide on our research blog